Merck Sends Assistance to Flood-Ravaged Thailand
- Details
- Category: Merck Group
Merck KGaA and its Life Science division Merck Millipore have sent thousands of state-of-the-art water test kits to Thailand in an effort to ensure the safety of municipal drinking water following months of devastating flooding in that region.
Pfizer to Acquire Excaliard Pharmaceuticals
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and Excaliard Pharmaceuticals, Inc. have entered into a definitive agreement under which Pfizer will acquire Excaliard, a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring.
Enbrel® (etanercept) Patent Issued
- Details
- Category: Amgen
Amgen announced the issuance of U.S. Patent No. 8,063,182 related to Enbrel® (etanercept). This patent is owned by Hoffman-La Roche Inc. ("Roche") and exclusively licensed to Amgen.
FDA Commissioner Announces Final Decision on Avastin for Metastatic Breast Cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the FDA Commissioner is revoking the approval of Avastin (bevacizumab) for the treatment of mBC in the United States.
Pfizer Wins Corporate Citizenship Award For Global Health Partnerships Program
- Details
- Category: Pfizer
Pfizer Inc. has received the 2011 Business Civic Leadership Center's Corporate Citizenship Award in the Best International Ambassador category for Pfizer's Global Health Partnerships program.
Novartis and collaborators discover new dual-acting class of antimalarial compounds
- Details
- Category: Novartis
The discovery of a new class of dual-acting antimalarial compounds - the imidazolopiperazines (IZPs) - was published in the journal Science online, at the Science Express website[1].
Genzyme and Cystic Fibrosis Foundation Therapeutics Announce Collaboration
- Details
- Category: Genzyme
Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), and Cystic Fibrosis Foundation Therapeutics Inc., the nonprofit affiliate of the Cystic Fibrosis Foundation, announced a research agreement to support the discovery of new drugs to treat people with the most common mutation found in patients with CF, Delta F508.
More Pharma News ...
- Bayer plans further expansion in Asia
- SATURN demonstrated effect of intensive statin treatment on reducing atherosclerosis
- Bristol-Myers Squibb Foundation's Together on Diabetes® Initiative Marks First Anniversary
- Thirteen Finalists Chosen for Boehringer Ingelheim and Ashoka Changemakers "Making More Health" Competition
- Lundbeck and Otsuka Pharmaceutical sign historic agreement
- Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
- Lundbeck's third quarter report 2011 - The positive momentum continues